d="ref22">   L. M. A. Jansen, I. E. van der Horst-Brwinsma, D. van Schaardenburg, P. D. Bezemer and B. A. C. Dijkmans, “Predictors of Radiographic Joint Damage in Patients with Early Rheumatoid Arthritis,” Annals of the Rheumatic Diseases, Vol. 60, No. 10, 2001, pp. 924-927. doi:10.1136/ard.60.10.924

[23]   J. Fries, P. W. Spit, R. G. Kraines and R. H. Holman, “Mea- surement of Patient Outcome in Arthritis,” Arthritis & Rheumatism, Vol. 23, No. 2, 1980, pp. 137-145. doi:10.1002/art.1780230202

[24]   A. Finckh, M. H. Liang, C. M. van Herckenrode, et al., “Long-Term Impact of Early Treatment on Radiographic Progression in Rheumatoid Arthritis: A Meta-Analysis,” Arthritis & Rheumatism, Vol. 55, No. 6, 2006, pp. 864-872. doi:10.1002/art.22353

[25]   H. Kallberg, L. Padyukov, R. M. Plenge, et al., “Gene-Gene and Gene-Environment Interactions Involving HLA-DRB1, PTPN22, and Smoking in Two Subsets of Rheumatoid Arthritis,” The American Journal of Human Genetics, Vol. 80, No. 5, 2007, pp. 867-875.

[26]   L. Klareskog, P. Stolt, K. Lundberg, et al., “A New Model for an Etiology of Rheumatoid Arthritis: Smoking May Trigger HLA-DR (shared epitope)—Restricted Immune Reactions to Autoantigens Modified by Citrullination,” Arthritis & Rheumatism, Vol. 54, No. 1, 2006, pp. 38-46. doi:10.1002/art.21575

[27]   M. Pedersen, S. Jacobsen, P. Garred, et al., “Strong Combined Gene-Environment Effects in Anti-Cyclic Citrullinated Peptide-Positive Rheumatoid Arthritis: A Nationwide Case-Control Study in Denmark,” Arthritis & Rheumatism, Vol. 56, No. 5, 2007, pp. 1446-1453. doi:10.1002/art.22597

[28]   M. M. Nielen, D. van Schaardenburg, H. W. Reesink, et al., “Specific Autoantibodies Precede the Symptoms of Rheumatoid Arthritis: A Study of Serial Measurements in Blood Donors,” Arthritis & Rheumatism, Vol. 50, No. 2, 2004, pp. 380-386. doi:10.1002/art.20018

[29]   S. Rantapaa-Dahlqvist, B. A. de Jong, E. Berglin, et al., “Antibodies against Cyclic Citrullinated Peptide and Arheumatoid Factor Predict the Development of Rheumatoid Arthritis,” Arthritis & Rheumatism, Vol. 48, No. 10, 2003, pp. 2741-2749.

[30]   M. K. Koivula, M. Heliovaara, J. Ramberg, et al., “Auto- antibodies Binding to Citrullinated Telopeptide of Type II Collagen and to Cyclic Citrullinated Peptides Predict Synergistically the Development of Seropositive Rheumatoid Arthritis,” Annals of the Rheumatic Diseases, Vol. 66, No. 11, 2007, pp. 1450-1455. doi:10.1136/ard.2006.062919

[31]   S. Nijenhuis, A. J. W. Zendman, E. R. Vossenaar, G. J. M. Pruijn, W. J. van Venrooij, “Autoantibodies to Citrullinated Proteins in Rheumatoid Arthritis: Clinical Performance and Biochemical Aspects of an RA-Specific Marker,” Clinica Chimica Acta, Vol. 350, No. 1-2, 2004, pp. 17-34. doi:10.1016/j.cccn.2004.07.016

[32]   G. Harauz, N. Ishiyama, C. M. Hill, I. R. Bates, D. S. Libich and C. Fares, “Myelin Basic Protein—Diverse Conformational States of an Intrinsically Unstructured Protein and Its Roles in Myelin Assembly and Multiple Sclerosis,” Micron, Vol. 35, No. 7, 2004, pp. 503-542. doi:10.1016/j.micron.2004.04.005

[33]   E. R. Vossenaar, A. J. W. Zendman, W. J. van Venrooij and G. J. M. Pruijn, “PAD, a Growing Family of Citrullinating Enzymes: Genes, Features and Involvement in Disease,” BioEssays, Vol. 25, No. 11, 2003, pp. 1106-1118.